A multicentric phase 2 study was conducted to determine the efficiency and the tolerance of imatinib mesylate in children with chronic myelogenous leukemia (CML) in advanced phase of the disease ...

Between December 1999 and June 2001, we treated 133 patients with chronic myeloid leukemia with imatinib mesylate according to Novartis Pharma protocols. 1,2 Among these 133 patients, 5 men and 4 ...

Leukemia - Imatinib mesylate-induced hepato-toxicity in chronic myeloid leukemia demonstrated focal necrosis resembling acute viral hepatitis Skip to main content Thank you for visiting nature.com.

Results of TETimaX Trial of Langerhans Cell Histiocytosis Treatment and Perspectives on the Role of Imatinib Mesylate in the Era of MAPK Signaling, Biomedicines, 9, 12, (1759), (2021). https://doi ...

Sun Pharma's Imatinib Mesylate Savings Card will also offer patients additional savings benefit of up to US$700 for a 30-day fill to offset any additional out-of-pocket cost should they be ...

The selective BCR-ABL1 kinase inhibitor imatinib mesylate (Gleevec) has been found to be safe and effective following almost 11 years of follow-up in patients with chronic myeloid leukemia.

As stated in the FDA approval letter, Sun Pharma’s Imatinib Mesylate ANDA contains a statement under section 505(j)(2)(A)(viii) of the FD&C Act representing that its application did not seek ...

A previous report of a randomized phase II trial of imatinib mesylate in patients with incurable GIST detailed high response rates at both the 400 and the 600 mg/d dose levels. We conducted a ...